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Leprosy: Prevention and Control
Vaseem Anjum
Abstract
Hansen’s disease is one of the most ancient diseases that is still prevalent in the 
world. The causative agent, Mycobacterium leprae (M. leprae) has a long incuba-
tion period, clinical features after infection are identified late and these acid 
fast bacilli cannot be cultured – making leprosy a difficult disease to eradicate. 
Therefore the prevention and control of disease becomes more important. The 
shift of treatment from dapsone monotherapy to multidrug therapy regimen has 
given a new hope. The multidrug therapy coupled with the newer vaccines promise 
better results to prevent further transmission. Globally and locally the efforts to 
decrease the burden of leprosy by using different strategies has resulted in elimina-
tion of leprosy. But there is still a long way to go to make world free of this dreaded 
disease.
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1. Introduction
Mycobacterium leprae (M. leprae) is an acid fast bacilli that is the causative 
agent of leprosy disease which mainly effects the skin and peripheral nerves. In 
olden times leprosy was common in temperate climates (e.g. Europe), today it 
is mainly confined to tropical and subtropical regions. Mode of transmission in 
leprosy is mainly through inhalation of droplets containing the bacteria. But skin 
contact is also claimed by many leprologists. The disabilities and deformities associ-
ated with leprosy due to neuropathy leads to long-term consequences, including. 
This in turn is associated with stigma.
The immunity of the host plays an important role in disease progress and 
control. Thus, fortunately 95% of patients exposed to M. leprae will not develop 
this disease. The variation in incubation period ranges from 2 to 20 years, or 
even longer.
Leprosy has been successfully eliminated as a public health problem in 
2000 globally and at the national level in 113 countries out of 122 by 2005 [1]. 
Elimination of leprosy is defined by World Health Organization as a point 
prevalence below 1 per 10,000 population [2]. However, the number of new 
patients diagnosed with leprosy is still significant, at more than 200,000 in 2016 
globally. The new case detection rate of the disease (NCDR) is only slowly declining 
(Figure 1) [3].
The long incubation period, silent symptoms, long duration MDT and unavail-
ability of effective vaccine makes this disease difficult to identify, treat and 
eradicate. To add to the misery the stigma associated with the disease is another 
challenge. In such circumstances, prevention and control of disease gains utmost 
importance.
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2. Burden of disease
In 2017, 192,713 patients were on treatment globally which makes the prevalence 
rate of 0.25 per 10,000 population [4]. Total of 210,671 new cases were reported 
in same year from 150 countries making NCDR of 2.77 per 100,000 population. 
Figure 2 below shows the trends over the past decade (2008–2017) in new case 
detection of leprosy cases globally in the reporting countries of World Health 
Organization (WHO) [4].
Figure 1. 
Trend in case detection and case detection rate, by WHO region, 2006–2016 [3].
Figure 2. 
Country-wise trends of detection of new leprosy cases from 2008 to 2017 [4].
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3. Control of leprosy
The three main goals of control of leprosy are
a. To detect the pathology early and treat the patient completely.
b. To prevent the transmission to the others.
c. To prevent the disabilities and other complications.
Thus the following modalities are adopted to control leprosy:
1. Medical measures
2. Social support
3. Program management
4. Evaluation
4. Medical measures
4.1 Estimation of the burden of leprosy
The control of leprosy starts with the estimation of size and magnitude of the 
problem. Most common epidemiological survey method of collection of data is 
“Quick random sample survey.” Information about the prevalence of leprosy, age 
and sex-wise distribution, various forms of leprosy and the health facilities avail-
able should be gathered. Roughly the total prevalence of leprosy in an area would be 
about 4 times that of the cases found among school children [5, 6]. These estimates 
are essential to plan, implement and to evaluate the results of the control program.
4.2 Early Case Detection
The objective is to detect all the cases as early as possible and to register 
them. Active case finding is important as the disease is symptomless in the early 
stages. Cases can be detected by the Contact surveys, Group surveys and Mass 
surveys. Contact surveys consists of examination of all household contacts with 
a lepromatous case, particularly children, in areas with prevalence less than 1 per 
1000. Contact surveillance of households is recommended for a minimum period of 
10 years after case is declared bacteriologically negative, and for 5 years in house-
holds with a non-lepromatous case from the time of diagnosis of the index case. 
Group surveys are done in areas where prevalence of leprosy is more than 1 in 1000 
population. This consists of screening certain groups such as school children, slum 
dwellers, military recruits, industrial workers, etc. through “Skin camps.” Lastly, 
mass surveys consists of examination of each and every individual by house-to-
house visits in hyperendemic areas (prevalence – 10 or more per 1000 population). 
These are generally carried out by repeated annual examinations of school children 
which yield better results at relatively low cost [5, 6]. The data of each case is 
entered in the standardized proforma developed by WHO.
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4.3 Chemotherapy
Since an effective vaccine is unavailable for leprosy the secondary preven-
tion (early treatment) becomes more important. Until 1981, Dapsone (Diamino 
Diphenyl Sulphone—DDS) was used to treat leprosy which resulted in the develop-
ment of resistance and relapse, making leprosy control difficult.
Multidrug Therapy: In 1982, WHO recommended Multidrug Therapy (MDT) 
for all leprosy patients. Introduction of MDT has opened a new avenue in the control 
of leprosy in the world. Aim of MDT is to convert the infectious case into noninfec-
tious as soon as possible, so as to reduce the reservoir of infection in the community.
The main objectives of MDT are:
• To ensure early detection of the cases.
• To interrupt the transmission of infection.
• To prevent drug resistance, relapse and reaction.
The advantages of MDT over dapsone monotherapy are:
1. Shorter duration of treatment,
2. Better patient compliance,
3. High cure rate,
4. Cost-effectiveness and
5. Ease in health delivery system.
There are two types of MDT regimens used depending on the symptoms 
and signs shown by the patients - Paucibacillary (PB) and Multibacillary (MB). 
Recommended Regimens are discussed below [3, 5–7]:
i. Multibacillary leprosy:
MDT is recommended for following groups of patients:
• All smear positive cases.
• Skin lesions more than five in number.
• More than one nerve trunk thickening.
• All cases of relapse/reactivation and all cases who have been treated with 
Dapsone monotherapy earlier.
The drugs used in Multibacillary MDT and dosages are:
Rifampicin: 600 mg once monthly, supervised.
Dapsone: 100 mg daily, self administered.
 Clofazimine: 300 mg once monthly, supervised and 50 mg daily, self 
administered.
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Duration of treatment for Multibacillary leprosy is 12 months, can be extended 
to 18 months and continued where possible up to smear negativity. Sometimes LL/
BL patients with high bacilli may need 2–3 years or more of MDT for achieving 
bacteriological negativity.
ii. Paucibacillary leprosy:
The drugs and dose schedule is:
Rifampicin 600 mg once a month for 6 months supervised.
Dapsone 100 mg daily for 6 months self administered.
Paucibacillary leprosy is treated for 6 months.
MDT is not contraindicated in patients with HIV infection.
 Each MDT blister pack contains tablets for 4 weeks treatment. For easy  
identification color coding of the blister pack is done, that is, with differ-
ent colors for multibacillary and paucibacillary cases both in adults and 
children.
The treatment in both PB and MB cases varies depending on the age of the 
patient. The patients between 10 to 14 years are treated as paediatric cases, 
while >14 years are considered adult. The standard treatment regimen for MB 
leprosy in adults is given for 12 months. The drugs in each blister pack are 
(Figure 3):
 Two capsules of Rifampicin of 300 mg (600 mg once a month) to be taken as 
single dose under supervision.
 Clofazimine 3 capsules of 100 mg each to be consumed once a month as single 
dose under supervision and 50 mg daily for next 28 days.
Dapsone 100 mg as single dose and then daily once for 1 month.
The standard adult treatment regimen for PB leprosy is (Figure 4):
Rifampicin: 600 mg once a month.
Dapsone: 100 mg daily.
Duration: 6 months (6 blister packs of 28 days each).
Figure 3. 
MDT for adult MB type of leprosy [2, 7].
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Treatment regimen for MB leprosy in children (ages 10–14 years) is (Figure 5):
Rifampicin: 450 mg once a month.
Clofazimine: 150 mg once a month, and 50 mg every other day.
Figure 4. 
MDT for adult PB type of leprosy [2, 7].
Figure 5. 
MDT for pediatric MB type of leprosy [2, 7].
Figure 6. 
MDT for pediatric PB type of leprosy [2, 7].
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Dapsone: 50 mg daily.
Duration: 12 months (12 blister packs of 28 days each).
Treatment regimen for PB leprosy in children (ages 10–14 years) is (Figure 6):
Rifampicin: 450 mg once a month.
Dapsone: 50 mg daily.
Duration: 6 months (6 blister packs of 28 days each).
MDT is provided free-of-charge globally through an agreement between a phar-
maceutical company and WHO. WHO manages distribution of MDT to countries in 
coordination with national leprosy programs.
5. Surveillance
Clinical surveillance of the patients after completion of treatment is an impor-
tant part of MDT to ensure complete cure. For paucibacillary cases follow up for at 
least once a year for 2 years after completion of treatment and for multibacillary 
cases at least once a year for 5 years [3–5].
6. Immunoprophylaxis
Early diagnosis of cases, aggressive treatment and proactive measures to avoid 
complications and disabilities is the backbone for the success of any comprehensive 
program. In addition to accurate reporting and control measures, effective preven-
tions will be needed to achieve elimination. Search for an effective vaccine either to 
be used alone or in combination with a drug has been going for a long time.
Presently BCG (Bacillus Calmette-Guerin) is the only vaccine that has shown 
some protection against M. leprae bacillus. A single dose of BCG gives 50 percent 
or higher protection against the disease. It is the most widely used vaccine in the 
world, yet the degree of protection it confers is not yet confirmed. The meta-anal-
ysis of many experimental studies concludes that the vaccine gives approximately 
26% protection against leprosy. But the protection level decreases with time. To 
overcome this problem more than one dose of vaccine is advised.
Other variants of vaccination are also suggested.
a. Adding killed M. leprae to BCG: Various modifications have been suggested, 
such as the addition of killed M. leprae to BCG. This method almost doubles the 
vaccine efficacy in some populations as concluded by few studies. But the same 
cannot be said for patients below 15 years.
b. Vaccination with M. indicus pranii (Mycobacterium W): This strain discov-
ered in India. Testing of the MIP vaccine took place in 2005 and showed that it 
was effective for seven to 8 years, after which a booster dose would be needed 
to maintain the immunity. Recently the vaccine was approved by the Drug 
Controller General of India to be rolled out in a project involving five districts 
in the states of Bihar and Gujarat, where there are high rates of leprosy. Leprosy 
patients and their close contacts will benefit from this project, making India the 
first country in the world to have a large-scale leprosy vaccination initiative [8].
Another milestone in prevention of leprosy is the discovery of the vaccine 
candidate, called LepVax. Scientists at Infectious Disease Research Institute 
(IDRI), along with national and international collaborators including the 
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National Hansen’s Disease Program and the National Institute of Allergy and 
Infectious Diseases (NIAID), part of the National Institutes of Health, with fi-
nancial support from American Leprosy Missions, have developed this leprosy 
vaccine. Based on the preclinical studies, the LepVax, has progressed to Phase 
I clinical testing in the United States, the first stage of safety testing in human 
volunteers. The clinical trial is focused not only on safety but also evaluates the 
immune response of the individual to the vaccine.
c. Indian cancer research center (ICRC) bacilli: Another variant belonging 
to the M. avium intracellulare group, the ICRC bacilli are thought to induce 
lepromin conversion in lepromatous leprosy patients and in lepromin-negative 
leprosy-free individuals. Its efficacy was reported to be 65.5 percent [8].
d. M. vaccae: The studies with this soil-dwelling mycobacterial species com-
bined with BCG showed to provide greater protection against leprosy, but a 
Vietnamese trial contradicted the results [8].
e. M. Habana: This bacilli has been reported to induce lepromin conversion when 
used as a live vaccine in monkeys, and protected mice against the development 
of leprosy [8].
Chemoprophylaxis alone provides two-year protective window while effective 
immunization will provide a much broader protective window. Thus many studies 
and research is going on to provide both chemoprophylaxis and immunization for 
immediate and short-term protection and longer-term protection respectively. This 
strategy could have better impact and distinct appeal in controlling and preventing 
leprosy. Such trials could also provide a gateway for the assessment and implemen-
tation of new emerging vaccines (Figure 7).
7. Chemoprophylaxis (post-exposure prophylaxis)
Chemoprohylaxis using effective antibiotics focuses on providing protection 
to people at risk such as close contacts – family members, neighbors, co-workers, 
health care providers for lepers etc. Due to the stigma of disease the leprosy cases 
Figure 7. 
Locations of leprosy vaccine testing.
9Leprosy: Prevention and Control
DOI: http://dx.doi.org/10.5772/intechopen.92089
are found in clusters in all endemic regions, rather than being evenly dispersed 
over the whole area. Thus these high risk people can be identified and prophylaxis 
provided along with secondary prevention strategies. The process includes focused 
surveillance, contact tracing, early diagnosis and treatment. This helps in reducing 
the incidence and breaking the chain of transmission.
Chemoprophylaxis, as recommended by WHO Guideline Development Group 
(GDG), is done using single dose rifampicin (SDR) for contacts of leprosy patients 
both in adults and children of 2 years of age and above. Before starting the drug 
leprosy and TB disease are to be excluded. There should be no contraindications also 
for the use of rifampicin.
Other important considerations for the implementation of this chemoprophy-
laxis by programs are:
i. Adequate management of contacts.
ii. Consent of the index case to disclose his/her disease.
An RCT found that SDR reduces risk of leprosy over 5–6 years in leprosy 
contacts. For every 1000 contacts treated with SDR, there were four leprosy cases 
prevented after 1–2 years and three cases prevented after 5–6 years.
Recommended dosage schedules for SDR are given in Table 1.
The limitations of this approach are:
a. The protection is approximately for only 2 years.
b. High bacillary load cannot be eliminated using single dose.
c. Specific screening test needed to distinguish between contacts with high and 
low bacillary load.
8. Deformity prevention and rehabilitation
Among communicable diseases, leprosy remains a leading cause of peripheral 
neuropathy and disability in the world, despite extensive efforts to reduce the 
disease burden. It is an important aspect of leprosy control. It means the medical, 
surgical, social, educational, and vocational restoration as far as possible of treated 
patients to normal activity so that they resume their place in the home, in society 
and industry [5–7]. Early treatment helps in disability limitation.
Rehabilitation: WHO has defined rehabilitation as “the combined and coordi-
nated use of medical, social, educational and vocational measures for training and 
retraining the individual to the highest possible level of functional ability.”
Age/weight Rifampicin single dose
Adults (≥15 years) 600 mg
10–14 years 450 mg
Children 6–9 years (weight ≥ 20 kg) 300 mg
Children <20 kg (≥2 years) 10–15 mg/kg
Table 1. 
Rifampicin dose for chemoprophylaxis [3].
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Preventive rehabilitation consists of prevention of development of disabilities 
in a leprosy patient by early diagnosis and prompt treatment. But once the patient 
becomes handicapped and suffers from the damage caused, should be trained and 
retrained to the maximum functional ability so that the patient becomes useful to 
self, to the family and to community at large by various measures such as medi-
cal (physical), surgical, psychological, vocational and social rehabilitation (Flow 
chart 20.10).
9. Health education
Health education is given to the patient, to the family and to the community at 
large about leprosy. The education should be directed to ensure general public and 
patients help them develop their own actions and efforts to change the perception 
about the disease and seeking professional help whenever required. Early recogni-
tion of symptoms, prompt diagnosis, health seeking behavior, personal care, treat-
ment adherence and rehabilitation are important aspects of health education. The 
key messages included are about the cause of disease and the complete cure avail-
able to encourage people for early diagnosis and treatment. It also aims at helping 
people to change their attitude and behavior by removing the misunderstandings 
and misconceptions. Mass Health education also helps to eradicate social stigma, 
social ostracism and social prejudice associated with leprosy which is the biggest 
hindrance for the eradication of disease.
10. Social and financial support
The complications of the disease cause disfigurement and disabilities which 
in turn gives way to the stigma and strong discrimination of these patients. This 
results not only in physical and social isolation also financial dependency, ulti-
mately forcing the leprosy patients to beg on streets for their survival. To address 
this issue WHO introduced the strategy of community-based rehabilitation (CBR). 
This intended to enhance the quality of life for lepers with disabilities through com-
munity initiatives. Community participation and using local resources to support 
the rehabilitation of people with disabilities within their own communities is the 
foundation of this concept [9, 10].
11. Programmatic measures
11.1 Prevention of leprosy globally
11.1.1  The enhanced global strategy for further reducing the disease burden due to 
leprosy 2011–2015
“Enhanced Global Strategy for Further Reducing the Disease Burden due to 
Leprosy for 2011–2015” was launched in 2009 by the World Health Organization. 
The target of the program was to reduce Grade 2 Disability rate (G2DR) in leprosy 
patients by at least 35% by the end of 2015 (G2DR is the number of new cases with 
grade 2 disability per 100,000 population). Since the elimination of leprosy in 2005, 
the prevalence is very less and thus G2DR has been proposed as an indicator. The 
advantage of G2DR as indicator is that, it is less susceptible to operational factors 
such as detection delay and is a more robust marker for mapping cases of leprosy in 
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any country. This will also help the program implementers to focus on interventions 
that reduce visible deformities by enhancing early detection and treatment of lep-
rosy patients and ultimately reduce the number of new leprosy cases in the popula-
tion. However by the end of 2015, only Thailand was able to achieve this target [11].
11.1.2 Global leprosy strategy 2016–2020: accelerating towards a leprosy-free world
In 2016, WHO launched the “Global Leprosy Strategy 2016–2020: Accelerating 
towards a leprosy-free world” [9].
The program aims to reinvigorate efforts to control leprosy and avert disabilities, 
especially among children still affected by the disease in endemic countries.
The strategy is built around three major pillars:
i. Strengthen government ownership and partnerships;
ii. Stop leprosy and its complications; and
iii. Stop discrimination and promote inclusion.
The strategy of this program is:
• To sustain expertise and increase the number of skilled leprosy staff;
• To improve the participation of affected persons in leprosy services;
• To reduce visible deformities and stigma associated with the disease;
• To call for renewed political commitment and enhanced coordination among 
partners;
• To highlight the importance of research and improved data collection and 
analysis.
The key interventions needed to achieve these targets include:
• Early case detection especially in children before visible disabilities occur thus 
reduce transmission;
• In highly endemic areas or communities detection of disease among higher risk 
groups through campaigns;
• Improving health care coverage and access for marginalized populations 
such as poor patients, patients in the difficult to reach areas and the areas of 
conflicts.
Customization of the strategic interventions in endemic countries is permitted 
to suit the national plans to meet the new targets. E.g. Screening all close contacts 
of persons affected by leprosy; initiating a shorter and uniform treatment regimen; 
and incorporating specific interventions against stigmatization and discrimination.
Its ultimate goal of this program is to further reduce the global and local leprosy 
burden, that is, (a) zero disabilities in children with leprosy-affected, (b) G2DR 
less than one per million population and (c) repeal of laws that discriminate leprosy 
patients of their rights.
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